Grober Ellen, Papp Kathryn V, Rentz Dorene M, Sperling Reisa A, Johnson Keith A, Amariglio Rebecca E, Schultz Aaron, Lipton Richard B, Ezzati Ali
Department of Neurology Albert Einstein College of Medicine and Montefiore Medical Center Bronx New York USA.
Harvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Alzheimers Dement (Amst). 2021 Dec 31;13(1):e12224. doi: 10.1002/dad2.12224. eCollection 2021.
To assess the relationship between memory performance defined by the Stages of Objective Memory Impairment (SOMI) system and the Alzheimer's disease (AD) ATN (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) biomarker system.
We used data from the Harvard Aging Brain Study cohort to estimate the level of ATN biomarkers: amyloid beta (C-Pittsburgh compound B-positron emission tomography [PET]), tau (F-18-flortaucipir [FTP] PET), and neurodegeneration (magnetic resonance imaging volumetrics). We assessed the cross-sectional relationship of SOMI classification with global amyloid levels, entorhinal and inferior temporal tau deposition, and hippocampal atrophy.
Participants with both memory storage and retrieval deficits (SOMI-3, -4) had smaller hippocampal volumes and higher entorhinal and inferior temporal tau burden than participants with no memory impairment (SOMI-0) or mild retrieval difficulty (SOMI-1). Amyloid burden did not differ among SOMI stages.
This pilot supports the close relationship between tau pathology and memory impairment across the AD continuum. SOMI may be useful to determine eligibility for randomized controlled trials prior to the assessment of biomarker status.
评估由客观记忆损害阶段（SOMI）系统定义的记忆表现与阿尔茨海默病（AD）的ATN（淀粉样蛋白β[A]、病理性tau蛋白[T]和神经退行性变[N]）生物标志物系统之间的关系。
我们使用了哈佛衰老大脑研究队列的数据来估计ATN生物标志物的水平：淀粉样蛋白β（C-匹兹堡化合物B正电子发射断层扫描[PET]）、tau蛋白（F-18-氟代托品[FTP]PET）和神经退行性变（磁共振成像容积测量）。我们评估了SOMI分类与整体淀粉样蛋白水平、内嗅区和颞下回tau蛋白沉积以及海马萎缩之间的横断面关系。
与无记忆损害（SOMI-0）或轻度检索困难（SOMI-1）的参与者相比，存在记忆存储和检索缺陷（SOMI-3、-4）的参与者海马体积更小，内嗅区和颞下回tau蛋白负担更高。SOMI各阶段之间的淀粉样蛋白负担没有差异。
这项初步研究支持了在AD连续体中tau蛋白病理与记忆损害之间的密切关系。在评估生物标志物状态之前，SOMI可能有助于确定随机对照试验的入选资格。
